{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:59:32Z","timestamp":1787896772934,"version":"build-2784847793"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ecl.2021.08.002","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T15:49:10Z","timestamp":1636559350000},"page":"781-792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Treatment of Hypercalcemia of Malignancy"],"prefix":"10.1016","volume":"50","author":[{"given":"Marlene","family":"Chakhtoura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"El-Hajj Fuleihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ecl.2021.08.002_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2021.08.002_bib3","first-page":"1551","article-title":"Cancer-induced hypercalcemia","volume":"29","author":"Lumachi","year":"2009","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.ecl.2021.08.002_bib4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1097-0142(19930215)71:4<1309::AID-CNCR2820710423>3.0.CO;2-M","article-title":"Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center","volume":"71","author":"Vassilopoulou-Sellin","year":"1993","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ecl.2021.08.002_bib5","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.2215\/CJN.02470312","article-title":"Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia","volume":"7","author":"Rosner","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ecl.2021.08.002_bib6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JOP.2016.011155","article-title":"Cancer-related hypercalcemia","volume":"12","author":"Goldner","year":"2016","journal-title":"J\u00a0Oncol Pract"},{"issue":"7","key":"10.1016\/j.ecl.2021.08.002_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-112-7-499","article-title":"Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients","volume":"112","author":"Ralston","year":"1990","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.ecl.2021.08.002_bib8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/07357907.2015.1047506","article-title":"Quality and outcomes of treatment of hypercalcemia of malignancy","volume":"33","author":"Wright","year":"2015","journal-title":"Cancer Invest"},{"issue":"12","key":"10.1016\/j.ecl.2021.08.002_bib9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1055\/a-1049-0647","article-title":"Diagnosis, pathophysiology and management of hypercalcemia in malignancy: a review of the literature","volume":"51","author":"Asonitis","year":"2019","journal-title":"Horm Metab Res"},{"issue":"5","key":"10.1016\/j.ecl.2021.08.002_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/00313025.2010.493868","article-title":"How paraproteins can affect laboratory assays: spurious results and biological effects","volume":"42","author":"king","year":"2010","journal-title":"Pathology"},{"issue":"5","key":"10.1016\/j.ecl.2021.08.002_bib12","first-page":"377","article-title":"Hypercalcemia and cancer: differential diagnosis and treatment","volume":"68","author":"Zagzag","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ecl.2021.08.002_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1159\/000188907","article-title":"Calcium-free hemodialysis for the management of hypercalcemia","volume":"72","author":"Koo","year":"1996","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.ecl.2021.08.002_bib14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0272-6386(97)90044-5","article-title":"Correction of hypercalcemia and hypophosphatemia by hemodialysis using a conventional, calcium-containing dialysis solution enriched with phosphorus","volume":"29","author":"Leehey","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ecl.2021.08.002_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-223772","article-title":"Treatment of extreme hypercalcaemia: the role of haemodialysis","volume":"2018","author":"Basok","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.ecl.2021.08.002_bib16","first-page":"473","article-title":"Rehydration in the treatment of severe hypercalcaemia","volume":"50","author":"Hosking","year":"1981","journal-title":"J\u00a0Assoc Physicians"},{"issue":"1","key":"10.1016\/j.ecl.2021.08.002_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/TME.0000000000000093","article-title":"Emergency management of malignancy-associated hypercalcemia","volume":"38","author":"Dellay","year":"2016","journal-title":"Adv Emerg Nurs J"},{"issue":"4","key":"10.1016\/j.ecl.2021.08.002_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-149-4-200808190-00007","article-title":"Narrative review: furosemide for hypercalcemia: an unproven yet common practice","volume":"149","author":"Legrand","year":"2008","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.ecl.2021.08.002_bib19","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/archinte.1990.00390210095021","article-title":"Fast and effective treatment of malignant hypercalcemia: combination of suppositories of calcitonin and a single infusion of 3-Amino 1-Hydroxypropylidene-1-","volume":"150","author":"Thi\u00e9baud","year":"1990","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.ecl.2021.08.002_bib20","first-page":"230","article-title":"Comparative study of incadronate and elcatonin in patients with malignancy-associated hypercalcaemia","volume":"30","author":"Matsumoto","year":"2002","journal-title":"J\u00a0Int Med Res"},{"issue":"2","key":"10.1016\/j.ecl.2021.08.002_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00298784","article-title":"Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy","volume":"50","author":"Fatemi","year":"1992","journal-title":"Calcified Tissue Int"},{"issue":"1","key":"10.1016\/j.ecl.2021.08.002_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF00296210","article-title":"Nasal human calcitonin for tumor-induced hypercalcemia","volume":"51","author":"Dumon","year":"1992","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"10.1016\/j.ecl.2021.08.002_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1060028020957048","article-title":"Bisphosphonate versus bisphosphonate and calcitonin for the treatment of moderate to severe hypercalcemia of malignancy","volume":"55","author":"Khan","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.ecl.2021.08.002_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00198-015-3339-z","article-title":"Does salmon calcitonin cause cancer? A review meta-analysis","volume":"27","author":"Wells","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2021.08.002_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.coph.2015.05.005","article-title":"Pharmacological diversity among drugs that inhibit bone resorption","volume":"22","author":"Russell","year":"2015","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"10.1016\/j.ecl.2021.08.002_bib29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2174\/157340612801216355","article-title":"Treatment of chronic hypercalcemia","volume":"8","author":"Camozzi","year":"2012","journal-title":"Med Chem"},{"issue":"1","key":"10.1016\/j.ecl.2021.08.002_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.1997.15.1.131","article-title":"Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy","volume":"15","author":"Vinholes","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"8461","key":"10.1016\/j.ecl.2021.08.002_bib31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(85)90848-7","article-title":"Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroidsicalcitonin in treatment of cancer-associated hypercalcaemia","volume":"326","author":"Ralston","year":"1985","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ecl.2021.08.002_bib32","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/bjc.1995.502","article-title":"A\u00a0randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy","volume":"72","author":"Purohit","year":"1995","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2021.08.002_bib33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.1992.10.1.134","article-title":"Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia","volume":"10","author":"Gucalp","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2021.08.002_bib34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2021.08.002_bib35","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s12032-010-9461-z","article-title":"Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study","volume":"28","author":"Sabry","year":"2011","journal-title":"Med Oncol"},{"issue":"8","key":"10.1016\/j.ecl.2021.08.002_bib36","first-page":"539","article-title":"Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate","volume":"11","author":"Pecherstorfer","year":"2003","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.ecl.2021.08.002_bib37","article-title":"Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis","author":"Jakob","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.ecl.2021.08.002_bib38","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.ecl.2021.08.002_bib39","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archinte.1987.00370050155026","article-title":"Maintenance etidronate in the prevention of malignancy-associated hypercalcemia","volume":"147","author":"Schiller","year":"1987","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.ecl.2021.08.002_bib42","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ejca.2015.04.017","article-title":"The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease","volume":"51","author":"Diel","year":"2015","journal-title":"Eur J Cancer"},{"issue":"9768","key":"10.1016\/j.ecl.2021.08.002_bib43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2021.08.002_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202861","article-title":"Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy","volume":"2014","author":"Adhikaree","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"2","key":"10.1016\/j.ecl.2021.08.002_bib45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155213518361","article-title":"Denosumab in hypercalcemia of malignancy: a case series","volume":"21","author":"Dietzek","year":"2015","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"9","key":"10.1016\/j.ecl.2021.08.002_bib46","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.clml.2015.06.007","article-title":"PTHrP-induced refractory malignant hypercalcemia in a patient with chronic lymphocytic leukemia responding to denosumab","volume":"15","author":"Salahudeen","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"10.1016\/j.ecl.2021.08.002_bib47","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.2169\/internalmedicine.55.7134","article-title":"Denosumab is effective for controlling serum calcium levels in patients with humoral hypercalcemia of malignancy syndrome: a case report on parathyroid hormone-related protein-producing cholangiocarcinoma","volume":"55","author":"Ashihara","year":"2016","journal-title":"Intern Med"},{"issue":"9","key":"10.1016\/j.ecl.2021.08.002_bib48","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2021.08.002_bib49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.amjmed.2014.09.030","article-title":"Hypercalcemic crisis: a clinical review","volume":"128","author":"Ahmad","year":"2015","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.ecl.2021.08.002_bib50","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/CAD.0000000000001051","article-title":"Novel bone-targeted parathyroid hormone-related peptide antagonists inhibit breast cancer bone metastases","volume":"32","author":"Ponnapakkam","year":"2021","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ecl.2021.08.002_bib51","unstructured":"Choppin A, Bedinger D, Hunt R, et al. A Novel anti-PTH1R receptor antagonist monoclonal antibody reverses hypercalcemia induced by PTH or PTHrP: a potential treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy. ENDO, Annual Meeting SAT 399, USA."},{"issue":"1","key":"10.1016\/j.ecl.2021.08.002_bib52","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-20-0487","article-title":"Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift","volume":"10","author":"O'Callaghan","year":"2021","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ecl.2021.08.002_bib53","first-page":"1779","article-title":"Hypercalcemia of malignancy and new treatment options","volume":"11","author":"Sternlicht","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"10.1016\/j.ecl.2021.08.002_bib54","article-title":"Hypercalcemia of malignancy treated with cinacalcet","volume":"2017","author":"Asonitis","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"6","key":"10.1016\/j.ecl.2021.08.002_bib57","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00774-016-0797-0","article-title":"Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism","volume":"35","author":"Takeuchi","year":"2017","journal-title":"J\u00a0Bone Miner Metab"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852921000761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852921000761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:46:39Z","timestamp":1760175999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852921000761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0889852921000761"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2021.08.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Hypercalcemia of Malignancy","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2021.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}